Compare · NVO vs TRAX
NVO vs TRAX
Side-by-side comparison of Novo Nordisk A/S (NVO) and First Tracks Biotherapeutics Inc. (TRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 134.9x TRAX ($1.29B).
- Over the past year, NVO is down 30.4% and TRAX is up 85.6% - TRAX leads by 115.9 points.
- TRAX has been more active in the news (6 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 12 for TRAX).
- Company
- Novo Nordisk A/S
- First Tracks Biotherapeutics Inc.
- Price
- $38.82-1.05%
- $34.48-4.29%
- Market cap
- $173.66B
- $1.29B
- 1M return
- -10.14%
- -11.93%
- 1Y return
- -30.36%
- +85.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 6
- Recent ratings
- 25
- 12
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest TRAX
- SEC Form 8-K filed by First Tracks Biotherapeutics Inc.
- First Tracks Biotherapeutics Announces $200 Million Private Placement
- SEC Form 8-K filed by First Tracks Biotherapeutics Inc.
- First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
- First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
- Canaccord Genuity initiated coverage on First Tracks Biotherapeutics with a new price target
- Evercore ISI initiated coverage on First Tracks Biotherapeutics with a new price target
- Director Orwin John A converted options into 1,300 shares, increasing direct ownership by 8% to 17,995 units (SEC Form 4)
- Guggenheim initiated coverage on First Tracks Biotherapeutics with a new price target
- SEC Form 144 filed by First Tracks Biotherapeutics Inc.